SOPHiA GENETICS (NASDAQ:SOPH) Sees Strong Trading Volume – Should You Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH) shares saw strong trading volume on Monday . 134,486 shares traded hands during trading, a decline of 43% from the previous session’s volume of 234,441 shares.The stock last traded at $8.65 and had previously closed at $8.65.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research boosted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright raised their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Stock Performance

The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a market cap of $716.84 million, a P/E ratio of -7.44 and a beta of 0.96. The stock’s 50 day moving average is $6.18 and its two-hundred day moving average is $5.32.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insider Buying and Selling

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction on Monday, August 10th. The stock was sold at an average price of $7.61, for a total transaction of $64,685.00. Following the completion of the transaction, the chairman directly owned 3,444,322 shares of the company’s stock, valued at approximately $26,211,290.42. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00. Following the completion of the sale, the chief technology officer owned 182,171 shares in the company, valued at $1,384,499.60. This represents a 2.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 318,592 shares of company stock valued at $1,952,315. 4.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the company. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS during the 4th quarter valued at about $49,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the third quarter worth about $49,000. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the first quarter worth about $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.